Latest news
- Jul 19, 2018 – Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody
- Jun 21, 2018 – Alligator Bioscience’s ATOR-1017 strongly activates both T cells and NK cells, important for the effective eradication of tumor cells
- May 29, 2018 – Alligator Bioscience Capital Markets Day today on May, 29
Latest News
- 19 Jul 2018 – Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody
- 12 Jul 2018 – Alligator Bioscience AB Interim Report January-June 2018
- 21 Jun 2018 – Alligator Bioscience’s ATOR-1017 strongly activates both T cells and NK cells, important for the effective eradication of tumor cells
Calendar
- 20 Aug 2018 — 23 Aug 2018 ‐ The Bispecific Antibody Pipeline Congress
- 27 Aug 2018 — 28 Aug 2018 ‐ 6th Annual Immunomodulatory Therapeutic Antibodies for Cancer conference, Boston
- 6 Sep 2018 ‐ Pareto Health Care Conference, Stockholm
- 10 Sep 2018 — 12 Sep 2018 ‐ NLSDays, Stockholm
- 26 Oct 2018 ‐ Interim Report Jul-Sep 2018
- 14 Feb 2019 ‐ Full Year Report 2018
Calendar
- Aug 20, 2018 - Aug 23, 2018 - The Bispecific Antibody Pipeline Congress
- Aug 27, 2018 - Aug 28, 2018 - 6th Annual Immunomodulatory Therapeutic Antibodies for Cancer conference, Boston
- Sep 6, 2018 - Pareto Health Care Conference, Stockholm
- Sep 10, 2018 - Sep 12, 2018 - NLSDays, Stockholm
- Oct 26, 2018 - Interim Report Jul-Sep 2018
Alligator Bioscience Capital Markets Day in Stockholm on May 29, 2018
Frontier
A magazine about Alligator Bioscience and immuno-oncology
